↓ Skip to main content

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, August 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis
Published in
Arthritis Research & Therapy, August 2014
DOI 10.1186/s13075-014-0415-2
Pubmed ID
Authors

Maria Greenwald, Leszek Szczepanski, Alastair Kennedy, Melissa Veenhuizen, Wendy J Komocsar, Emery Polasek, Kelly Guerrettaz, Pierre-Yves Berclaz, Chin Lee

Abstract

IntroductionThe objective of this study was to evaluate the long-term safety and efficacy of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B-cell activating factor, in rheumatoid arthritis (RA) patients.MethodsPatients with RA who completed one of two 24-week randomized controlled trials (RCTs) participated in this 52-week, flexible-dose, open-label extension study. Patients in RCT1 received intravenous placebo, 30-mg tabalumab, or 80-mg tabalumab every three weeks, and patients in RCT2 received subcutaneous placebo or 1-, 3-, 10-, 30-, 60-, or 120-mg tabalumab every four weeks (Q4W). Regardless of prior treatment, all patients in this study received subcutaneous 60-mg tabalumab Q4W for the first three months, then a one-time increase to 120-mg tabalumab Q4W (60/120-mg group) and a one-time decrease to 60-mg Q4W per patient was allowed (60/120/60-mg group).ResultsThere were 182 patients enrolled: 60-mg (n¿=¿60), 60/120-mg (n¿=¿121), and 60/120/60-mg (n¿=¿1). Pre-tabalumab baseline disease activity was generally higher for the 60/120-mg group. There was a higher frequency of serious adverse events and treatment-emergent adverse events, as well as infections and injection-site reactions, in the 60/120-mg group. One death unrelated to study drug occurred (60/120-mg group). For both groups, total B-cell counts decreased approximately 40% from baseline of the RCT originating study. Both groups demonstrated efficacy on American College of Rheumatology criteria improvement ¿20%, ¿50%, and ¿70%, European League Against Rheumatism Responder Index in 28 joints, Disease Activity Score in 28 joints¿C-reactive protein, and Health Assessment Questionnaire¿Disability Index with 52 weeks of treatment relative to baseline pre-tabalumab disease activity.ConclusionsWith long-term, open-label tabalumab treatment, no unexpected safety signals were observed, and B-cell reductions were consistent with previous findings. Despite differences in RCT-originating studies, both groups demonstrated an efficacy response through the 52-week extension.Trial registrationClinicalTrials.gov NCT00837811. Registered 3 February 2009.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Unknown 60 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 18%
Student > Bachelor 9 15%
Researcher 8 13%
Student > Postgraduate 5 8%
Student > Ph. D. Student 5 8%
Other 7 11%
Unknown 17 27%
Readers by discipline Count As %
Medicine and Dentistry 23 37%
Nursing and Health Professions 7 11%
Agricultural and Biological Sciences 4 6%
Biochemistry, Genetics and Molecular Biology 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Other 2 3%
Unknown 21 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2014.
All research outputs
#20,655,488
of 25,371,288 outputs
Outputs from Arthritis Research & Therapy
#2,907
of 3,380 outputs
Outputs of similar age
#181,120
of 247,841 outputs
Outputs of similar age from Arthritis Research & Therapy
#37
of 47 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,841 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.